Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UniCAR02-T-CD123 in CD123-positive hematologic malignancies
NCT04230265Phase 1Terminated
- Sponsor
- AvenCell Therapeutics
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Autologous CAR-T
- Countries
- 2
01
Overview
Phase 1, open-label trial of AVC-101 in acute myeloid leukemia (AML) (2 arms), sponsored by AvenCell Therapeutics. Primary endpoints: Safety and tolerability at 3 months, Recommended phase 2 dose at 34 days and 1 more. Started Jan 2020; status: terminated.
02
Drugs
AVC-101
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04230265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230265.